EGFR and non-small cell lung carcinoma: By using the first crizotinib resistant METex14 NSCLC PDX, our result provided evidence in vivo to support using bispecific antibody as a clinical strategy to overcome EGFR-driven MET TKIs resistant NSCLC (38–41).